Announced
Financials
Sources
Tags
Pending
Friendly
Single Bidder
United States
biotechnology
biological development
Biotechnology
Acquisition
Cross Border
Majority
Private
Synopsis
Sanofi, a global healthcare company, agreed to acquire Inhibrx, a clinical-stage biopharmaceutical company, for $1.7bn. “The addition of INBRX-101 as a high potential asset to our rare disease portfolio reinforces our strategy to commit to differentiated and potential best-in-class products. With our expertise in rare diseases and growing presence in immune-mediated respiratory conditions, INBRX-101 will complement our approach to deploy R&D efforts in key areas of focus and address the needs of the underserved AATD patients and communities,” Houman Ashrafian, Sanofi Head of Research and Development.
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.